Ipsen S.A. – Product Pipeline Review

Global Markets Direct’s, ‘Ipsen S.A. – Product Pipeline Review – 2016’, provides an overview of the Ipsen S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ipsen S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Ipsen S.A.

The report provides overview of Ipsen S.A. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Ipsen S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Ipsen S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Ipsen S.A.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ipsen S.A.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ipsen S.A.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Ipsen S.A. Snapshot 7

Ipsen S.A. Overview 7

Key Information 7

Key Facts 7

Ipsen S.A. - Research and Development Overview 8

Key Therapeutic Areas 8

Ipsen S.A. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Ipsen S.A. - Pipeline Products Glance 17

Ipsen S.A. - Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Phase III Products/Combination Treatment Modalities 18

Ipsen S.A. - Clinical Stage Pipeline Products 19

Phase II Products/Combination Treatment Modalities 19

Phase I Products/Combination Treatment Modalities 20

Phase 0 Products/Combination Treatment Modalities 21

Ipsen S.A. - Early Stage Pipeline Products 22

Preclinical Products/Combination Treatment Modalities 22

Discovery Products/Combination Treatment Modalities 23

Ipsen S.A. - Drug Profiles 24

lanreotide acetate 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

abobotulinumtoxin A 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

abobotulinumtoxin A next generation 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

triptorelin pamoate PR 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

BN-82451 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

BIM-23A758 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

3BP-227 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Peptides for Endocrine Gland Disorders 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Peptides for Oncology and Genito Urinary System And Sex Hormones 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Peptides to Antagonize ACTH Receptor for Cushing's Syndrome 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Recombinant Protein 1 to Inhibit SNARE for Neurology 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Recombinant Protein 1 to Target SNAP-25 for Movement Disorders 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Recombinant Protein 2 to Inhibit SNARE for Neurology 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Recombinant Protein 3 to Target SNAP-25 for Movement Disorders 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

STX-140 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

STX-681 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

SXN-101742 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

SXN-101959 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Drugs to Antagonize Androgen Receptor for Prostate Cancer 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Peptides for Endocrine Disease 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Recombinant Protein 2 to Target SNAP-25 for Movement Disorders 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Recombinant Protein 4 to Target SNAP-25 for Movement Disorders 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Ipsen S.A. - Pipeline Analysis 49

Ipsen S.A. - Pipeline Products by Target 49

Ipsen S.A. - Pipeline Products by Route of Administration 51

Ipsen S.A. - Pipeline Products by Molecule Type 52

Ipsen S.A. - Pipeline Products by Mechanism of Action 53

Ipsen S.A. - Recent Pipeline Updates 54

Ipsen S.A. - Dormant Projects 61

Ipsen S.A. - Discontinued Pipeline Products 62

Discontinued Pipeline Product Profiles 62

BIM-23A760 62

(mecasermin + somatropin) 62

irosustat 62

taspoglutide 62

Ipsen S.A. - Company Statement 63

Ipsen S.A. - Locations And Subsidiaries 64

Head Office 64

Other Locations & Subsidiaries 64

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Tables

List of Tables

Ipsen S.A., Key Information 7

Ipsen S.A., Key Facts 7

Ipsen S.A. – Pipeline by Indication, 2016 9

Ipsen S.A. – Pipeline by Stage of Development, 2016 11

Ipsen S.A. – Monotherapy Products in Pipeline, 2016 12

Ipsen S.A. – Partnered Products in Pipeline, 2016 13

Ipsen S.A. – Partnered Products/ Combination Treatment Modalities, 2016 14

Ipsen S.A. – Out-Licensed Products in Pipeline, 2016 15

Ipsen S.A. – Out-Licensed Products/ Combination Treatment Modalities, 2016 16

Ipsen S.A. – Pre-Registration, 2016 17

Ipsen S.A. – Phase III, 2016 18

Ipsen S.A. – Phase II, 2016 19

Ipsen S.A. – Phase I, 2016 20

Ipsen S.A. – Phase 0, 2016 21

Ipsen S.A. – Preclinical, 2016 22

Ipsen S.A. – Discovery, 2016 23

Ipsen S.A. – Pipeline by Target, 2016 49

Ipsen S.A. – Pipeline by Route of Administration, 2016 51

Ipsen S.A. – Pipeline by Molecule Type, 2016 52

Ipsen S.A. – Pipeline Products by Mechanism of Action, 2016 53

Ipsen S.A. – Recent Pipeline Updates, 2016 54

Ipsen S.A. – Dormant Developmental Projects,2016 61

Ipsen S.A. – Discontinued Pipeline Products, 2016 62

Ipsen S.A., Subsidiaries 64

List of Figures

List of Figures

Ipsen S.A. – Pipeline by Top 10 Indication, 2016 9

Ipsen S.A. – Pipeline by Stage of Development, 2016 11

Ipsen S.A. – Monotherapy Products in Pipeline, 2016 12

Ipsen S.A. – Partnered Products in Pipeline, 2016 13

Ipsen S.A. – Out-Licensed Products in Pipeline, 2016 15

Ipsen S.A. – Pipeline by Top 10 Target, 2016 49

Ipsen S.A. – Pipeline by Route of Administration, 2016 51

Ipsen S.A. – Pipeline by Molecule Type, 2016 52

Ipsen S.A. – Pipeline Products by Top 10 Mechanism of Action, 2016 53

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports